Novo Nordisk's November Calendar: Liver Presentations, a Washington Obesity Congress and the 4 November Earnings Test
Published on 10/31/2026 at 14:31 | Editorial boerse-global.de
Novo Nordisk has stacked its autumn schedule with scientific presentations and a financial reckoning, giving investors several distinct checkpoints to weigh rather than a single catalyst. The Danish drugmaker confirmed on Wednesday that it will present new liver data covering Wegovy at a 2.4 mg dose and the investigational candidate Efruxifermin at The Liver Meeting, the annual gathering of the American Association for the Study of Liver Diseases (AASLD).
That disclosure is a scheduling notice, not a trial win or a regulatory ruling. What matters is the substance of the results themselves, which will determine whether the data point to added medical or commercial value for Novo. Keeping the announcement date separate from the findings is central to reading the news correctly.
A Second Congress, a Different Focus
Two days earlier, on Thursday, the company had flagged a separate batch of obesity research. A total of 26 scientific abstracts are slated for ObesityWeek, running from 14 to 17 November in Washington, spanning CagriSema and the Wegovy tablet, including data on how the pill performs in routine care. The two conferences pull in different directions: the liver meeting centres on Wegovy and Efruxifermin, while the Washington event leans on the obesity franchise. For shareholders, the value lies in the results, not the headcount of presentations.
CagriSema: A Post-Hoc Signal With Limits
One concrete data point arrived on 20 October, when Novo released a retrospective analysis of the REDEFINE 1 trial. Among women with obesity or overweight, CagriSema produced an average weight loss of 25.0% after 68 weeks — a figure that assumes continuous adherence to therapy. The findings were presented at the annual meeting of the Menopause Society.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Those caveats are part of the headline, not footnotes. The result cannot be extrapolated to the full study population, nor framed as independent of treatment compliance. It is, moreover, a post-hoc analysis — a look back at existing trial data — and should not be confused with a fresh approval decision.
Such a decision did land on 23 October, when the FDA cleared Awiqli as the first once-weekly basal insulin for children aged ten and older with type 2 diabetes, according to the company.
The Lilly Yardstick
Competitive context continues to be set by Eli Lilly. Reuters reported on Thursday on robust demand for Lilly's injectable weight-loss drugs and a widening lead over Novo in the GLP-1 market. That is more than a friendly sector signal; it sharpens the pressure on Novo. It does not, however, explain the stock's move on Friday, when the shares added 2.7% — a gain that coincided with a more favourable industry mood following Lilly's own results, though no direct link between that report and Novo's advance has been established.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The 4 November Print
All of this funnels toward 4 November, when Novo publishes results for the first nine months of 2026. Recent approval and study announcements offer encouraging footholds, but whether they translate into financial progress is a separate question — and the earnings release is the next hard test. Distinguishing market potential from corporate execution matters here: strong demand for obesity medicines alone does not settle how Novo is faring against its rivals, which is why the upcoming numbers carry more weight for assessment than any single good session on the exchange.
The sequence of proof points is therefore layered — financial performance first, further scientific findings after. Medical advances bolster the product outlook; only the figures can show how the business is actually developing.
Ad
Novo Nordisk Stock: New Analysis - 31 October
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
